Andrew Conrad

Nusano, Inc. is a privately held medical technology company that is committed to bringing stability and innovation to the medical radioisotopes market. The company is based in Valencia, CA. The company's proprietary ion source is smaller and more efficient than existing production methods, which allows for the simultaneous manufacturing of multiple radioisotopes. Nusano's state-of-the-art production facility will open in the first quarter of 2025. The company's technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development. Christopher P. Lowe has been the CEO of the company since 2022.

Nusano, Inc. is a privately held medical technology company that is committed to bringing stability and innovation to the medical radioisotopes market. The company is based in Valencia, CA. The company's proprietary ion source is smaller and more efficient than existing production methods, which allows for the simultaneous manufacturing of multiple radioisotopes. Nusano's state-of-the-art production facility will open in the first quarter of 2025. The company's technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development. Christopher P. Lowe has been the CEO of the company since 2022.

Nusano, Inc. is a privately held medical technology company that is committed to bringing stability and innovation to the medical radioisotopes market. The company is based in Valencia, CA. The company's proprietary ion source is smaller and more efficient than existing production methods, which allows for the simultaneous manufacturing of multiple radioisotopes. Nusano's state-of-the-art production facility will open in the first quarter of 2025. The company's technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development. Christopher P. Lowe has been the CEO of the company since 2022.

Nusano, Inc. is a privately held medical technology company that is committed to bringing stability and innovation to the medical radioisotopes market. The company is based in Valencia, CA. The company's proprietary ion source is smaller and more efficient than existing production methods, which allows for the simultaneous manufacturing of multiple radioisotopes. Nusano's state-of-the-art production facility will open in the first quarter of 2025. The company's technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development. Christopher P. Lowe has been the CEO of the company since 2022.